KLK3 and neoplasm: Prostate-specific antigen (PSA), a serine protease of 30–34 kDa produced by epithelial prostatic cells, is the main biomarker for the diagnosis, screening and monitoring of patients with prostate cancer and eventually the first tumour biomarker approved by the Food and Drug Administration (FDA) [187].